23andMe Investor Presentation Deck

Preclinical Data Supports Combining CD96 with PD-1 and TIGIT Inhibitors CD96, TIGIT and PD-1 Combination Suggests Synergy Mean tumor size (mm²) 200- 150- 100- 50- 0 0 clg aCD96- BαPD1 A&TIGIT (G2a)- aCD96 + aTIGIT (G2a) CPD1 + aCD96 *aPD1 + αTIGIT (G2a) e aPD1 + @TIGIT (G2a) + aCD96 5 10 15 20 25 30 35 40 45 50 Days after CT26 tumor inoculation Cancer Immunol Res. 2019;7(4):559 55 Anti-CD96 + Anti-TIGIT+ Anti-PD1 Combination CD226 axis components owned by GSK Component Molecule PD-1 CD96 PVRIG TIGIT Dostarlimab GSK'608 SRF813 GSK4428859 (EOS448) Partner Acquired from Tesaro 23andMe In-license from Surface Oncology iTeos Copyright © 2022 23and Me, Inc. 23andMe 40

View entire presentation